- Gene Therapy
- Drug
Spinal Muscular Atrophy (SMA) Treatment Market size was valued at USD 2.22 billion in 2021 and is expected to reach USD 13.11 billion by 2028, at a CAGR of 28.9% during the forecast period 2022-2028. Due to increase in awareness regarding the disease (SMA), increase in the research for the rare disease treatment, initiative by government and private organizations to create awareness about the disease SMA, increase in number of initiatives for the treatment procedures of rare diseases, innovation of drugs and other therapies for the treatment and complex nature of the disease are the major factors that are driving the growth of the global spinal muscular atrophy (SMA) treatment market over the forecast timeframe. This report studies global spinal muscular atrophy (SMA) treatment market dynamics elaborately to indentify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global spinal muscular atrophy (SMA) treatment market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global spinal muscular atrophy (SMA) treatment market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the approval of orphan drugs especially in spinal muscular atrophy (SMA) and growing number of R&D activities for the orphan drugs are the factors that drive the growth of market. For instance, in 2017, USFDA granted an orphan drug license for the treatment of spinal muscular atrophy that is RG7916 which is a development programme by Roche, SMA foundation, and PTC therapeutics. These approvals are expected to increase the research in the field of orphan drugs and are anticipated to propel the global spinal muscular atrophy (SMA) treatment market over the forecast years.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.